SCHEMBL277606

SCHEMBL277606

CS(=O)(=O)Nc1ccc2nc(-c3cccc(N=O)c3)[nH]c(=O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MET P08581 6/20 0.47
KCNH2 Q12809 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HSP90AA1 P07900 1/20 0.41
GAA P10253 1/20 0.41
THRB P10828 1/20 0.41
TNKS O95271 1/20 0.40
PARP1 P09874 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
MAPK14 Q16539 1/20 0.40
CDK4 P11802 1/20 0.40
CCND1 P24385 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259298 0.81 GUSB (0.64) METKCNH2NPC1RAB9ALMNA
SCHEMBL273167 0.78 GUSB (0.51) NPC1RAB9AALDH1A1TNKSPARP1
SCHEMBL277870 0.78 TNKS (0.56) NPC1RAB9ATNKSPARP1TNKS2
SCHEMBL11920135 0.78 KDM4E (0.54) NPC1RAB9AALDH1A1LMNATNKS
SCHEMBL11919793 0.74 GUSB (0.55) NPC1RAB9AALDH1A1TNKSTNKS2
SCHEMBL13030213 0.74 KDM4E (0.54) METKCNH2NPC1RAB9AALDH1A1
SCHEMBL10138647 0.70 KEAP1 (0.53) NPC1RAB9AALDH1A1LMNA
SCHEMBL12592059 0.69 PDE5A (0.46) METKCNH2ALDH1A1LMNAHSP90AA1
SCHEMBL11919210 0.68 GUSB (0.50) TNKSTNKS2CDK4CCND1
SCHEMBL13318680 0.68 KDM4E (0.60) NPC1RAB9AALDH1A1GAATNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A MET 518/4885KCNH2 3277/4885NPC1 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.